Liquidia Corporation Reports Third Quarter 2026 Financial Results
Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026 · October 2026 total patient shipments reached thei
How this was made
The 30-second read
Why it matters
The settlement charge creates a sizable net loss, but strong sales and pipeline progress could support the stock long‑term.
Market read
First‑hand earnings and settlement disclosure provides fresh data for traders; immediate price reaction expected.
What to watch
Fast Track designation and expanding pipeline may offset settlement drag over the next 12‑18 months.
YUTREPIA net product sales of $222.7 million in Q3 2026, up 31% sequentially; net loss of $236.3 million driven by a $389.7 million litigation settlement charge
Commercial momentum is strong: product sales rose to $222.7 million from $51.7 million a year earlier and the company reports record October shipments. Against that, the quarter carries a $389.7 million litigation settlement charge that produced a $236.3 million net loss, stockholders' equity turned to a deficit of $(25,434) thousand, and the company agreed to pay net $380.7 million in installments through 2027.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product sales, net (three months ended Sep 30, 2026)GAAP | $222.7M | up 31% from Q2 2026 | $171.0 million increase |
| Service revenue, net (three months ended Sep 30, 2026)GAAP | $2.56M | – | – |
| Total revenue (three months ended Sep 30, 2026)GAAP | $225.3M | – | – |
| Cost of product sales (three months ended Sep 30, 2026)GAAP | $14M | – | $11.7 million increase |
| Cost of service revenue (three months ended Sep 30, 2026)GAAP | $792K | – | – |
| Research and development expenses (three months ended Sep 30, 2026)GAAP | $25.3M | – | $16.0 million or 170% increase |
| Selling, general and administrative expenses (three months ended Sep 30, 2026)GAAP | $59M | – | $18.9 million or 47% increase |
| Litigation settlement, net (three months ended Sep 30, 2026)GAAP | $389.7M | – | – |
| Total costs and expenses (three months ended Sep 30, 2026)GAAP | $488.8M | – | – |
| (Loss) income from operations (three months ended Sep 30, 2026)GAAP | −$263.5M | – | – |
| Interest expense, net (three months ended Sep 30, 2026)GAAP | $2.9M | – | $2.4 million decrease |
| Loss before income taxes (three months ended Sep 30, 2026)GAAP | −$266.4M | – | – |
| Income tax benefit (three months ended Sep 30, 2026)GAAP | $30.1M | – | – |
| Net loss (three months ended Sep 30, 2026)GAAP | $236.3 million net loss | – | – |
| Net loss per common share, basic and diluted (three months ended Sep 30, 2026)GAAP | $(2.64) | – | – |
| EBITDA (three months ended Sep 30, 2026)non-GAAP | −$263.0M | – | – |
| Adjusted EBITDA (three months ended Sep 30, 2026)non-GAAP | $140.5 million ($140,453 thousand) | – | – |
| Paid patient demand, excluding voucher and patient access programs (three months ended Sep 30, 2026)other | $212.2M | – | – |
| Cash and cash equivalents (as of Sep 30, 2026, prior to settlement payments)GAAP | $396.1M | – | – |
| YUTREPIA prescriber base (through October 2026)other | 1,300 prescribers | – | – |
| Conversion of monthly referrals to patient starts (as of October 31, 2026)other | above 87% | – | – |
| Daily referral rate in October 2026 (as a share of Q3 2026 daily referral rate)other | more than 75% | – | – |
| Referrals including a PAH diagnosis (launch through September 2026)other | more than 60% | – | – |
| Referrals including a PAH diagnosis (September 2026)other | more than 70% | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| YUTREPIA (treprostinil) inhalation powder, product sales, netThe company states the increase of $171.0 million was due to higher volume of YUTREPIA sales. Shipments to US customers began in June 2025 after full FDA approval in May 2025. Company states October 2026 total patient shipments reached their highest monthly level since launch. Company also states it has ceased promoting YUTREPIA for PH-ILD following the settlement. | $222.7M | up 31% from Q2 2026 | $171.0 million increase |
| Service revenue, net (Sandoz Promotion Agreement, Treprostinil Injection)Revenue related to the Promotion Agreement with Sandoz, Inc., under which profits from US sales of Treprostinil Injection were shared. The company states the agreement was terminated in October 2026 and it will no longer generate service revenue. | $2.6M | – | – |
Capital returns
- No share repurchases or dividends are reported in the documents.
- The company states the settlement payments are expected to be funded from current cash and cash equivalents and ongoing sales of YUTREPIA.
What drove it
- The company states product sales growth reflects higher volume of YUTREPIA sales.
- The company states cost of product sales increased primarily due to higher volume of YUTREPIA sales.
- The company states R&D increased by $16.0 million or 170%, primarily due to an $11.1 million increase in expenses for the L606 program, a $3.2 million increase in YUTREPIA R&D activities, and a $1.2 million increase in personnel expenses driven by higher headcount.
- The company states SG&A increased by $18.9 million or 47%, primarily due to a $6.4 million increase in personnel expenses, a $5.5 million increase in stock-based compensation driven by higher headcount, and a $4.1 million increase in commercial and consulting expenses to support the commercialization of YUTREPIA.
- The company states interest expense decreased by $2.4 million, primarily attributable to higher money market balances and lower interest accretion under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P.
- The company states the litigation settlement charge of $389.7 million consists of $330.4 million payable to United Therapeutics, less $10.0 million receivable from United Therapeutics, $60.3 million payable to parties with interests in the antitrust litigation, and other non-cash write-offs of assets related to the Promotion Agreement.
- The company states YUTREPIA sales led to a fifth consecutive quarter of increasing non-GAAP adjusted EBITDA, which was $140.5 million.
Concerns
- Net loss of $236.3 million, or $(2.64) per share, includes the $389.7 million litigation settlement charge.
- Total stockholders' equity moved to a deficit of $(25,434) thousand as of September 30, 2026, from $44,748 thousand as of December 31, 2025.
- Total liabilities rose to $708,376 thousand from $283,186 thousand as of December 31, 2025, and the company agreed to pay net $380.7 million in installments in 2026 and 2027.
- Service revenue ended because the Sandoz Promotion Agreement was terminated in October 2026.
- The company states it ceased promoting YUTREPIA for PH-ILD and submitted a Prior Approval Supplement to remove the PH-ILD indication from the label.
- Income tax benefit of $30.1 million was recognized in the quarter, and the company did not recognize any income tax benefit in Q3 2025.
What to watch
- Timing and outcome of the FDA review of the Prior Approval Supplement to remove the PH-ILD indication from the YUTREPIA label, and the company's statement on the impact of ceasing PH-ILD promotion and sales on YUTREPIA revenue.
- Installment payments under the settlement agreement in 2026 and 2027, and the company's funding from cash and ongoing YUTREPIA sales.
- Paid patient demand and shipment trends following the record October 2026 shipment month the company reports.
- Progress of the Phase 4 studies in PAH (LTI-403, SPRINT, EASY-PAH) and the RE-WARM Phase 2 study in SSc-RP, with primary study completion timing as stated.
- L606 program milestones, including Re-Spire enrollment completion anticipated in 2028, AMPLIFY-PAH enrollment initiation anticipated in 2027, and PH-COPD pivotal study initiation anticipated in the second half of 2027.
- Operating expense trend, given R&D and SG&A increases of 170% and 47% year over year as reported.
Balance sheet and cash flow
- Cash and cash equivalents: $396,091 thousand as of September 30, 2026, versus $190,680 thousand as of December 31, 2025. The release states this is prior to the payments under the settlement agreements.
- Total assets: $682,942 thousand as of September 30, 2026, versus $327,934 thousand as of December 31, 2025.
- Total liabilities: $708,376 thousand as of September 30, 2026, versus $283,186 thousand as of December 31, 2025.
- Accumulated deficit: $(735,057) thousand as of September 30, 2026, versus $(626,313) thousand as of December 31, 2025.
- Total stockholders' (deficit) equity: $(25,434) thousand as of September 30, 2026, versus $44,748 thousand as of December 31, 2025.
- Under the settlement agreement, Liquidia agreed to pay net $380.7 million in multiple installments in 2026 and 2027, inclusive of payments to other parties to resolve the antitrust litigation against United Therapeutics related to Treprostinil Injection.
- The release does not report operating cash flow, free cash flow or capital expenditures.
Analysis
Liquidia reported third quarter 2026 total revenue of $225,300 thousand, against $54,342 thousand a year earlier. Product sales, net were $222.7 million versus $51.7 million, an increase the company attributes to higher YUTREPIA volume, and the release states product sales rose 31% from the second quarter of 2026. Service revenue of $2.6 million came from the Sandoz Promotion Agreement, which the company says was terminated in October 2026 and will no longer generate service revenue. The company also reports $212.2 million in paid patient demand excluding voucher and patient access programs, more than 60% of referrals since launch including a PAH diagnosis, and 1,300 prescribers through October. It states that October 2026 total patient shipments were the highest monthly level since launch.
Costs rose faster than revenue on several lines. Cost of product sales increased to $14.0 million from $2.3 million, which the company links to higher YUTREPIA volume. R&D expenses increased to $25.3 million from $9.3 million, and SG&A increased to $59.0 million from $40.1 million. The company attributes the R&D increase mainly to the L606 program and the SG&A increase mainly to personnel, stock-based compensation and commercial and consulting spend. Operating results were a loss from operations of $(263,519) thousand, against income from operations of $1,767 thousand in the prior-year quarter, because of the $389.7 million litigation settlement, net line.
The settlement dominates the GAAP result. The company states the charge includes $330.4 million payable to United Therapeutics, less $10.0 million receivable, $60.3 million payable to parties with interests in the related antitrust litigation, and non-cash write-offs tied to the Promotion Agreement. Net loss was $236.3 million, or $(2.64) per basic and diluted share, against a net loss of $3.5 million, or $(0.04) per share, a year earlier. A $30.1 million income tax benefit was recognized, and the release reports no such benefit in the prior-year quarter. The company's non-GAAP adjusted EBITDA was $140.5 million, which it describes as the fifth consecutive quarter of increase. The reconciliation adds back the settlement charge and $13,678 thousand of stock-based compensation to a reported EBITDA of $(262,974) thousand.
The balance sheet changed materially. Cash and cash equivalents were $396.1 million at September 30, 2026, before settlement payments, compared with $190.7 million at December 31, 2025. Total liabilities increased to $708,376 thousand from $283,186 thousand, and stockholders' equity moved from $44,748 thousand at December 31, 2025 to a deficit of $(25,434) thousand. The company states it agreed to pay net $380.7 million in installments during 2026 and 2027 and expects to fund those payments from current cash and ongoing YUTREPIA sales. The release does not report operating cash flow, free cash flow or any capital return.
The release gives no quantitative guidance for the coming periods. The most consequential forward items are regulatory and clinical: the Prior Approval Supplement to remove the PH-ILD indication from the YUTREPIA label, the stated cessation of PH-ILD promotion, the Phase 4 PAH studies, the RE-WARM Phase 2 study in SSc-RP with Fast Track designation, and the L606 pivotal programs. The company's own forward-looking statements caveat that the settlement does not extend to indications other than PAH and that United Therapeutics may assert patents against development programs. Readers should weigh the reported October shipment record and referral trends against the settlement cash outflows and the wider operating expense base.
Management, verbatim
With the litigation now fully resolved, and YUTREPIA’S commercial availability secure, we can fully focus on cementing the value of YUTREPIA through Phase 4 studies in PAH that will position it as the best-in-class inhaled therapy and first-in-choice prostacyclin.
Dr. Roger Jeffs, Chief Executive Officer
Not in the filing
stated, not guessed- Prior-quarter (Q2 2026) values for most line items, including product sales, total revenue, operating expenses and net loss, are not printed in the release, so qoq values are null except the stated 31% sequential increase in product sales.
- Year-over-year percentage changes for total revenue, cost of service revenue, litigation settlement, operating loss, net loss and EPS are not printed.
- Operating cash flow, free cash flow, capital expenditures and cash flow statement figures are not reported.
- Full-year or year-to-date (nine-month) results are not included in the release.
- Guidance for revenue, gross margin, operating expenses or tax rate is not provided in the documents.
- No previous-release outlook was supplied, so no comparison against prior guidance is possible.
- Analyst consensus estimates, price targets and share-price reaction are not in the documents.
- Gross margin percentage is not printed.
- Prior-year and prior-quarter comparisons for cash and balance sheet items are given against December 31, 2025 rather than a prior-year or prior-quarter date, so they are shown in balance_sheet_cash_flow instead of key_metrics comparison fields.
- Settlement-related payment schedule by year is not broken out beyond the 2026 and 2027 timing and the net $380.7 million total.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Liquidia Corp (NASDAQ:LQDA) reported its third‑quarter 2026 financials, detailing product sales growth and a major litigation settlement with United Therapeutics.
Ticker impact
Liquidia Corp disclosed Q3 2026 results, including $380.7M settlement payment and $222.7M product sales.
downward pressure as investors price in the $380M settlement charge despite revenue growth
The settlement is a one‑time cash outflow of $380.7M, increasing loss to $236.3M, which typically triggers a sell‑off.
Market effects
Highlights settlement risk in biotech pharma litigation, may affect peer inhaled‑therapy companies.
US biotech sector could see modest pullback as investors reassess litigation exposures.
Limited to US‑listed biotech; no broader macro impact.
Counterpoint
Settlement clears legal uncertainty; future cash flow from YUTREPIA could drive upside despite short‑term loss.
Key entities
- CompanyLiquidia Corp
Biopharma company developing inhaled prostacyclin therapies.
- CompanyUnited Therapeutics
Counterparty in the $380.7M settlement.
